Biodesix, Inc. (NASDAQ:BDSX) Q2 2023 Earnings Call Transcript

And so we’re excited about that. Getting the Oracle data out now when we could give them more time to digest it, to research it on their own. And so we fully expect to have great robust conversation there. And then the second part, yes. I was just going to say sorry, go ahead, Yuko.

Yuko Oku: No, no, no, go ahead.

Scott Hutton: Yes. So for us, when we look towards interim data on altitude, it really is going to be based upon enrollment. We’re very pleased with enrollment, we’ve had a number of back-to-back months with record number of enrollments. So I don’t expect to have interim data or analysis that we’d be sharing at CHEST because we would already be doing that analysis. I think as we get closer to the end of the year, we’ll look at that and maybe do an interim analysis share sooner in the year next year, not waiting for CHEST. But it’s critically important for us. We know that a prospective randomized trial in this space is significant, more excited to get that data out there. And we’re really proud to be working with a number of major academic institutions that we are on that study.

Yuko Oku: Great. Thank you so much for the color.

Scott Hutton: Yes. Thank you, Yuko

Operator: Thank you for your question. This now concludes our question-and-answer session. I’d now like to pass the call back over to Scott Hutton, Chief Executive Officer for Biodesix for closing remarks.

Scott Hutton: Thank you, operator. We’ve worked long and hard to build the best pulmonology focused sales team in diagnostics. And I think that’s just the beginning of our growth. With a first-mover status in lung nodule management and an ever-increasing body of robust clinical data, we’re eager to provide updates on our progress and how we continue to build on the momentum already created, as we increase our clinical data and payer adoption in this extremely large market opportunity. Ultimately, it’s all about physicians and the patients they treat, and we believe in our ability to make a more significant impact in the future. Our research, development and laboratory teams are continuously delivering on operational improvements and cost savings, maintaining a high level of compliance and positively impacting our already strong gross margins while exceeding our standard of best-in-class operations as evidenced by our unmatched turnaround times on test results delivery.

We’ve prioritized a quality-focused Biodesix team and culture and trust that our cost discipline approach and resulting reduction in operating expense and cash burn will provide greater clarity and assurance around our path to profitability. We look forward to updating you on our continued progress and successes on the next earnings call and hosting you in our new state-of-the-art and highly accredited facility soon. Thank you.

Operator: Thank you. This concludes today’s conference call. Thank you for participating. You may now disconnect.